Log in to your Inderes Free account to see all free content on this page.

Cessatech

16.30 DKK

-1.21 %

Less than 1K followers

CESSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-1.21 %

-1.81 %

-15.98 %

+2.13 %

+38.61 %

+22.74 %

+773.99 %

-7.41 %

+51.14 %

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company focuses on specialty products designed for use in clinical settings and advances its programs through a partnership-based development model. Founded in 2020, Cessatech is headquartered in Denmark and led by a team with experience across drug development and commercialization.

Market cap

302.8M DKK

Turnover

290.41K DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

28.5.

2026

Interim report Q1'26

28.8.

2026

Interim report Q2'26

26.11.

2026

Interim report Q3'26

All

Press releases

ShowingAll content types

Regulatory press release3/30/2026, 9:45 AM

Minutes from the Annual General Meeting in Cessatech A/S

Regulatory press release3/13/2026, 7:30 AM

Cessatech convenes its Annual General Meeting

Regulatory press release2/27/2026, 7:30 AM

Cessatech A/S Announces Financial Results for the Full Year 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/2/2026, 7:00 AM

Cessatech: Welcome to the first quarter of 2026

Regulatory press release11/13/2025, 7:30 AM

Cessatech: Third Quarter Report Q3-2025

Regulatory press release10/31/2025, 12:00 PM

Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children

Regulatory press release8/21/2025, 6:30 AM

Cessatech: Second Quarter Report Q2-2025

Regulatory press release8/14/2025, 4:00 PM

Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children

Press release6/27/2025, 11:31 AM

Cessatech Q&A - June company presentation

Regulatory press release6/19/2025, 11:30 AM

Cessatech strengthens Executive Management with the promotion of Martin Juhl

Regulatory press release6/11/2025, 12:15 PM

Cessatech announce completion of the directed issue of shares

Regulatory press release5/28/2025, 8:30 PM

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch

Regulatory press release5/28/2025, 3:30 PM

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch

Regulatory press release5/28/2025, 3:15 PM

Cessatech announces positive top-line results from its final CT001 Study 0202

Regulatory press release5/15/2025, 6:30 AM

Cessatech: First Quarter Report Q1-2025

Regulatory press release4/30/2025, 1:45 PM

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001

Regulatory press release3/28/2025, 10:30 AM

Minutes from the Annual General Meeting in Cessatech A/S

Regulatory press release3/12/2025, 7:30 AM

Cessatech: Annual General Meeting - 28 March 2025

Regulatory press release2/28/2025, 7:30 AM

Cessatech A/S publishes Annual Report for the fiscal year 2024

Regulatory press release2/4/2025, 10:30 AM

Cessatech receives positive Notified Body opinion under MDR for CT001

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.